Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | OTC | P00480 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | ARG2 | P78540 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL18149039 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL1696994 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL18149040 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL19181970 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL8957537 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL714211 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL3516723 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL11660904 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL15022773 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL4954180 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | claimed |
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-114929274-A | Use of succinic acid as biomarker for cancer diagnosis and treatment | 台湾卫生研究院 | 2022-08-19 | — | — | CN | disclosed |
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-3909606-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | Astellas Pharma Inc. (JP) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909608-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | Astellas Pharma Inc. (JP) | 2021-11-17 | — | — | EP | disclosed |
| CN-113301920-A | Complexes comprising ligands, spacers, peptide linkers and biomolecules | 安斯泰来制药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| CN-113271973-A | Complex comprising a ligand and a CEACAM5 antibody Fab fragment | 安斯泰来制药株式会社 | 2021-08-17 | — | — | CN | disclosed |
| EP-3816183-A1 | ANTIBODY LIBRARY AND ANTIBODY SCREENING METHOD USING SAME | Mogam Institute for Biomedical Research (KR) | 2021-05-05 | — | — | EP | disclosed |
| CN-112424221-A | Antibody library and antibody screening method using same | 财团法人牧岩生命科学研究所 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020145228-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145227-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | GSR 4068/4885OTC 4635/4885GNAI3 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.